ESR1 and breast carcinoma: We further assessed FABP4 expression across different breast cancer subtypes, including hormone sensitive (ER + /PR + /HER2-), HER2 positive (ER-/PR-/HER2 +), and triple negative (ER-/PR-/HER2-).